Drug Profile
MK 2461
Latest Information Update: 22 Mar 2010
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Solid tumours